{"id":"enoxaparin-clopidogrel-aspirin","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding/hemorrhage"},{"rate":"1-3","effect":"Thrombocytopenia"},{"rate":"2-5","effect":"Injection site reactions (enoxaparin)"},{"rate":"3-8","effect":"Dyspepsia"},{"rate":"2-5","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enoxaparin is a low-molecular-weight heparin that inhibits factors Xa and IIa in the coagulation cascade. Clopidogrel and aspirin are antiplatelet agents that work synergistically—clopidogrel inhibits ADP-mediated platelet activation via P2Y12 receptor antagonism, while aspirin irreversibly inhibits cyclooxygenase and thromboxane A2 production. Together, this triple therapy provides comprehensive antithrombotic coverage.","oneSentence":"This combination uses enoxaparin (anticoagulant), clopidogrel (antiplatelet), and aspirin (antiplatelet) to prevent thrombotic events through multiple pathways of coagulation and platelet inhibition.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:28.736Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI)"},{"name":"Thromboembolism prevention in high-risk cardiovascular patients"}]},"trialDetails":[{"nctId":"NCT05705089","phase":"PHASE3","title":"Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI","status":"COMPLETED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2020-07-30","conditions":"Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction","enrollment":50},{"nctId":"NCT02835534","phase":"PHASE4","title":"The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI","status":"COMPLETED","sponsor":"CSPC Mingfule Pharmaceutical (Guangzhou) Co., Ltd.","startDate":"2016-05","conditions":"Acute ST Elevation Myocardial Infarction","enrollment":818},{"nctId":"NCT00669149","phase":"PHASE4","title":"Anticoagulant Treatments and Percutaneous Coronary Angioplasty","status":"TERMINATED","sponsor":"Centre Hospitalier de PAU","startDate":"2008-06","conditions":"Coronary Artery Disease","enrollment":99},{"nctId":"NCT02893280","phase":"","title":"Acute Coronary Syndrome Sri Lanka Audit Project","status":"WITHDRAWN","sponsor":"University of Colombo","startDate":"2015-04","conditions":"Acute Coronary Syndrome, Unstable Angina, Non ST Elevation Myocardial Infarction","enrollment":""},{"nctId":"NCT02131103","phase":"NA","title":"The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2014-01","conditions":"ST-elevation Myocardial Infarction","enrollment":130},{"nctId":"NCT00954928","phase":"","title":"The Safety of Hand Surgery in the Anticoagulated Patient","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-06","conditions":"Hand Surgery","enrollment":398},{"nctId":"NCT00238667","phase":"PHASE3","title":"To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2005-11","conditions":"Cervical Artery Dissection, Carotid Artery Dissection, Vertebral Artery Dissection","enrollment":250},{"nctId":"NCT02268669","phase":"PHASE4","title":"Comparison of Primary PCI vs. Post-thrombolysis PCI as Reperfusion Strategies in STEMI","status":"UNKNOWN","sponsor":"GRACIA Group","startDate":"2010-05","conditions":"Myocardial Infarction","enrollment":1444}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lovenox Plavix Kardégic"],"phase":"marketed","status":"active","brandName":"enoxaparin + clopidogrel + aspirin","genericName":"enoxaparin + clopidogrel + aspirin","companyName":"Centre Hospitalier de PAU","companyId":"centre-hospitalier-de-pau","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination uses enoxaparin (anticoagulant), clopidogrel (antiplatelet), and aspirin (antiplatelet) to prevent thrombotic events through multiple pathways of coagulation and platelet inhibition. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI), Thromboembolism prevention in high-risk cardiovascular patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}